AstraZeneca Results Presentation Deck

Respiratory & Immunology: nirsevimab First immunisation to show benefit in a general infant population Synagis is the only antibody approved for prevention in high- risk infants¹ with RSV² RSV-related hospitalisations (%) 15% 10% 5% Building on Synagis launched in 1998 0% 10.6% placebo ↓55% reduction 4.8% SYNAGIS 8 PALIVIZUMAB Over 20 years of experience in RSV prevention with Synagis 1. Children of premature birth (less than or equal to 35 weeks) or bronchopulmonary dysplasia 2. Respiratory syncytial (virus). Source: Pediatrics, 1998, 102(3):531-537. 29 nirsevimab Phase IIb trial had strong results³ 70% lower rate of medically- attended RSV-associated lower respiratory tract infection 78% lower rate of hospitalisation RSV-related hospitalisations (%) 5% 0% 4.1% placebo ↓78% reduction 0.8% nirsevimab c.30 million infant lower respiratory tract infections per year, globally 3. Population: healthy infants born early (29 weeks, 0 days to 34 weeks 6 days of gestation). Sources: The New England Journal of Medicine, 13 August 2020, 13;383(7):698 and AstraZeneca epidemiology estimate. In collaboration with Sanofi. nirsevimab MELODY Phase III trial showed positive data Positive efficacy readout in general infant population. Protection across the entire RSV season with one dose Trial continues for safety MEDLEY Phase II/III trial also anticipated to read out early First regulatory submission anticipated in 2022 3

View entire presentation